Indian heart journal最新文献

{"title":"Serial electrocardiographic changes in patients with idiopathic dilated cardiomyopathy","authors":"Anil Kumar Choudhary,&nbsp;Ajay Bahl,&nbsp;Yash Paul Sharma,&nbsp;Saurabh Mehrotra,&nbsp;Himanshu Gupta,&nbsp;Somyata Somendra","doi":"10.1016/j.ihj.2025.02.010","DOIUrl":"10.1016/j.ihj.2025.02.010","url":null,"abstract":"<div><div>Broad QRS and bundle-branch blocks are associated with poor outcomes in patients with DCM, however, studies on changes in QRS duration and morphology over long-term are limited. We retrospectively analyzed changes in ventricular activation and AV conduction in serial ECGs of 165 DCM patients with a follow-up of at least 5 years from 2003 to 2022. The mean QRS duration at the last follow-up was 114.2 ± 29 vs 106.2 ± 25.3 msec at the baseline(<em>p</em> &lt; 0.0001). Individuals who showed ≥10msec increase in QRS duration also had a higher prevalence of ventricular conduction defects (68%). 13.8% of patients developed broadening of QRS, with an LBBB pattern in over 50%.</div></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"77 2","pages":"Pages 114-116"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nuclear imaging studies in patients with an indeterminate diagnosis of infective endocarditis: A retrospective analysis of a case series","authors":"Ísis da Capela Pinheiro ,&nbsp;Alysson Selton Santiago ,&nbsp;Vitor Deriquehem de Araújo Silva ,&nbsp;Lucas Ferreira de Oliveira ,&nbsp;Rebeca Maria Gomes Guimarães Alves ,&nbsp;Ana Glória Bucar ,&nbsp;João Mansur Filho ,&nbsp;Lúcia Helena Alvares Salis ,&nbsp;Nelson Albuquerque de Souza e Silva ,&nbsp;Roberto Muniz Ferreira","doi":"10.1016/j.ihj.2025.03.008","DOIUrl":"10.1016/j.ihj.2025.03.008","url":null,"abstract":"<div><h3>Objectives</h3><div>To determine the role of nuclear imaging (NI) in evaluating inconclusive cases with suspicion of infective endocarditis (IE).</div></div><div><h3>Methods</h3><div>Consecutive patients with an indeterminate diagnosis of IE who underwent labelled leucocyte scintigraphy (LS) or ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) between 2018 and 2021 at 2 reference hospitals in Rio de Janeiro were retrospectively analysed. Subsequent confirmed or rejected diagnoses of IE were evaluated, in addition to clinical and imaging data. Kappa coefficient was used to compared the diagnostic agreement between echocardiographic and NI findings, with a <em>p</em>-value &lt;0.05 considered statistically significant.</div></div><div><h3>Results</h3><div>A total of 85 NI scans (28 FDG-PET/CT, 57 LS) from 76 patients were evaluated, of whom 48 (63.2 %) underwent only LS, 19 (25 %) only FDG-PET/CT, and 9 (11.8 %) both studies. Average age was 63.8 years (SD ± 18.5) and 51.3 % were women. Prosthetic valves were present in 15.8 % of cases, and intracardiac devices in 10.5 %. Among the 76 patients, 18 (23.7 %) had NI findings suggestive of IE. A total of 28 patients (36.8 %) were ultimately diagnosed with IE, 28.6 % of whom had confirmed infections by NI scans. Echocardiographic results had a low level of agreement with NI findings in those diagnosed with IE (kappa = −0.44).</div></div><div><h3>Conclusions</h3><div>Nuclear imaging contributed to the diagnosis of IE in approximately 30 % of subsequently confirmed cases, which were initially classified as inconclusive by echocardiography. The low level of agreement between these methods underscores their complementary role in the diagnosis of IE, particularly in indeterminate cases.</div></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"77 2","pages":"Pages 93-97"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early experience with the “modified jailed balloon technique” for side branch protection in bifurcation lesions","authors":"Somyata Somendra,&nbsp;Himanshu Gupta,&nbsp;Yash Paul Sharma","doi":"10.1016/j.ihj.2025.02.011","DOIUrl":"10.1016/j.ihj.2025.02.011","url":null,"abstract":"<div><h3>Objective</h3><div>M-JBT is a novel approach to the \"keep-it-open strategy\" for bifurcation lesions where SB anatomy is unsuitable for stenting. We intend to provide insight into a contemporary way through our experience of the M-JBT.</div></div><div><h3>Methods</h3><div>A semi-compliant balloon sized appropriately for the SB diameter is inflated simultaneously with the MB stent balloon during stent deployment, followed by POT of the MB stent and then recrossing the SB.</div></div><div><h3>Results</h3><div>We performed the “M-JBT” in 25 cases of bifurcation lesions between September 2023–24, with absolute procedural success in preventing SB occlusion during MB stenting in all 25 lesions. SB occlusion after MB stent POT was seen in one case.</div></div><div><h3>Conclusion</h3><div>This is the first report of clinical experience with the MJBT from the Indian subcontinent. MJBT proves to be a safe and effective approach to the protection of a clinically important SB during MB stenting across it.</div></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"77 2","pages":"Pages 89-92"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-coated balloon in patients with in-stent restenosis: A prospective observational study","authors":"Shuvanan Ray ,&nbsp;Siddhartha Bandyopadhyay ,&nbsp;Prithwiraj Bhattacharjee ,&nbsp;Priyam Mukherjee ,&nbsp;Suman Karmakar ,&nbsp;Pallab Bose ,&nbsp;Basabendra Choudhury ,&nbsp;Deepankar Paul ,&nbsp;Avik Karak","doi":"10.1016/j.ihj.2025.03.003","DOIUrl":"10.1016/j.ihj.2025.03.003","url":null,"abstract":"<div><h3>Aim</h3><div>The aim of this study was to compare the safety and efficacy of paclitaxel-coated balloons (PCB) and sirolimus-coated balloons (SCB) in patients with in-stent restenosis (ISR).</div></div><div><h3>Methods</h3><div>This prospective, observational, single-centre pilot study enrolled 85 patients diagnosed with drug-eluting stent ISR. For all the eligible patients, various clinical baseline characteristics were collected, and angiography was performed to evaluate the lesion characteristics. After assessment, patients were treated with either PCB or SCB based on our center's time-based approach. Intravascular ultrasound (IVUS) imagining was used to assess the pre- and post-procedural minimal stent area (MSA). All the patients were followed up and major adverse cardiovascular events were documented for patients in both the groups.</div></div><div><h3>Results</h3><div>Of total 85 patients with ISR, 32 underwent treatment with PCB and 53 with SCB. A significant difference was noted in the post procedural MSA in both the groups (<em>p</em> = 0.005) and the values were 7.01 ± 1.11 mm² and 8.01 ± 1.70 mm² for PCB and SCB group, respectively. At median follow-up of 3.8 years, no cardiac death was noted in PCB group and one death was reported in SCB group (<em>p</em> = 0.459). In PCB group, target lesion revascularization (TLR) was noted in one (12.5 %) patient, while in SCB group TLR was noted in four (16.5 %) patients (<em>p</em> = 0.920).</div></div><div><h3>Conclusion</h3><div>Both PCB and SCB are found to be effective and safe in treating in patients with drug-eluting stents-ISR. Also, the use of DCB with imaging techniques like IVUS enhances treatment outcomes and optimizes patient care in ISR treatment.</div></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"77 2","pages":"Pages 105-109"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and outcomes of PCI with novel tapered coronary stent in people living with HIV: A prospective, single-center study with literature review","authors":"H.S. Natraj Setty,&nbsp;B.H. Natesh,&nbsp;M.C. Yeriswamy,&nbsp;V.A. Sathwik Raj,&nbsp;Rahul S. Patil,&nbsp;H.B. Chetan Kumar,&nbsp;L. Sridhar Shastry,&nbsp;B.C. Srinivas,&nbsp;Babu Reddy,&nbsp;Jayashree Kharge,&nbsp;C.M. Nagesh,&nbsp;S. Manohar,&nbsp;C.M. Satwik,&nbsp;K.H. Srinivas,&nbsp;Santhosh Jadav,&nbsp;K.S. Subramani,&nbsp;Sadanand,&nbsp;Vijay Kumar,&nbsp;K.S. Ravindranath","doi":"10.1016/j.ihj.2025.03.001","DOIUrl":"10.1016/j.ihj.2025.03.001","url":null,"abstract":"<div><h3>Background and objective</h3><div>Patients with chronic HIV infection face a high risk of premature coronary atherosclerosis, partly due to continuous HAART therapy and susceptibility to opportunistic infections, complicating percutaneous coronary intervention (PCI). HIV patients have unique coronary vasculature characteristics. This study aimed to assess the clinical outcomes of PCI using the novel tapered sirolimus-eluting coronary stent (SES) system in HIV patients.</div></div><div><h3>Methods</h3><div>A prospective, single-arm, non-randomized study was conducted at a tertiary cardiac care center, including 15 HIV-positive patients with acute coronary syndromes. PCI was performed using the study device for de novo coronary lesions with significant size disparity between reference vessel segments. The cumulative incidence of major adverse cardiovascular events (MACE), defined as cardiac death, myocardial infarction, and clinically driven target-lesion revascularization (CD-TLR), was the primary endpoint.</div></div><div><h3>Results</h3><div>Since 2018, 15 HIV-positive patients with a mean age of 50.67 years underwent PCI with the study device. Despite cardiac risk factors and complex lesions, 100 % procedural and device success was achieved by restoring myocardial flow (TIMI flow III). Over a median follow-up of 40 months, no MACE or adverse events were recorded.</div></div><div><h3>Conclusions</h3><div>This study provides new evidence on the use of the long, tapered SES for treating HIV-positive patients, demonstrating high success rates and favorable long-term outcomes. It is the first report of such outcomes using a long, tapered SES in this population.</div></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"77 2","pages":"Pages 117-121"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factor XI and XII inhibitors–Dawn of a new era","authors":"Chhabi Satpathy,&nbsp;Trinath Kumar Mishra,&nbsp;Anshu Kumar Jha","doi":"10.1016/j.ihj.2025.02.007","DOIUrl":"10.1016/j.ihj.2025.02.007","url":null,"abstract":"<div><div>The history of coagulation cascade dates back to 17th century. The extrinsic and intrinsic pathways were proposed in 1998. Extrinsic pathway includes the tissue factor and stable factor which activates factor X and with help of factor V, this converts prothrombin to thrombin which is stabilised by factor XIII. This helps to seal the bleeding vessel and is a physiological process as there is only “limited” production of thrombin which doe not expand beyond the damaged site due to absence of tissue factor. On the other hand intrinsic pathway is activated by polyanions, neutrophilic extracellular traps which are present during infection and inflammation. These activate factor XI which activates factor X with the help of factor IX and VIII and then the common pathway ensues. But newer discoveries have shown that this is a very simplified way of explaining the coagulation system. The researches propose that haemostasis is divided into initiation, amplification and propagation phase. Also, the factor VII-tissue factor complex formed activates factor IX and leads to sustained thrombin production as the amount of thrombin produced by extrinsic pathway alone is not sufficient to form a haemostatic plug. Thrombin also activates factor XI and lead to self perpetuation of intrinsic pathway.</div><div>All the anticoagulants have an inherent property of bleeding. So the newer factor XI and XII inhibitors focus to inhibit the excessive thrombin production without hampering the physiological haemostasis process. This is supported by the fact that congenital factor XI and XII deficiency does not cause excessive bleeding but increased levels did make patients more vulnerable to thromboembolism.</div><div>This review shall focus on the various factor XI and XII inhibitors which are in the pipeline.</div></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"77 2","pages":"Pages 122-129"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanistic of intrinsic valvular inflammation in rheumatic heart disease","authors":"Ertan Yetkin","doi":"10.1016/j.ihj.2025.03.005","DOIUrl":"10.1016/j.ihj.2025.03.005","url":null,"abstract":"","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"77 2","pages":"Page 131"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory cytokine levels in rheumatic heart disease and their association with use of benzathine penicillin: A case-control pilot study","authors":"Sanjeev Kumar ,&nbsp;Prakash Chand Negi ,&nbsp;Sanjeev Asotra ,&nbsp;Meenakshi Chandel ,&nbsp;Jitender Kumar ,&nbsp;Rajeev Merwah ,&nbsp;Rajesh Sharma ,&nbsp;Ritesh Kumar ,&nbsp;Vinay Bhardwaj ,&nbsp;Preetam Singh Thakur","doi":"10.1016/j.ihj.2025.01.007","DOIUrl":"10.1016/j.ihj.2025.01.007","url":null,"abstract":"<div><h3>Background</h3><div>Valvular inflammation plays an important role in the progression of Rheumatic Heart Disease. We report the association between inflammatory markers and use of Benzathine Penicillin G in patients with Rheumatic mitral valve disease.</div></div><div><h3>Methods</h3><div>The levels of inflammatory cytokines; IL-1β, IL-6, TNF-α and inflammatory marker hs- CRP were measured using ELISA method in 32 patients with RHD receiving Benzathine Penicillin as secondary prophylaxis and 31 patients not receiving secondary prophylaxis, in a case–control study. The severity and type of valvular dysfunction were assessed with echocardiogram.</div></div><div><h3>Results</h3><div>The median level of IL-1β was significantly lower in patients on BPG (0.95 pg/ml vs. 5.47 pg/ml) <em>p</em> &lt; 0.002. The median levels of IL-6, TNF-α and hs-CRP were not significantly different between study groups. The adjusted odds of raised IL-1β were lower in patients on BPG (odds ratio 0.40, 95 % C.I. 0.11, 1.45) <em>p</em> 0.16. There was a trend of inverse association between the use of BPG and mitral stenosis (odds ratio 0.42, 95 % C.I. (0.12, 1.46) <em>p</em> 0.17.</div></div><div><h3>Conclusion</h3><div>Patients with RHD on BPG had lower levels of IL-1β and a trend toward a lower prevalence of mitral stenosis. Role of IL-1β in progression of incompetent to stenotic mitral valve dysfunction needs to be explored in future studies.</div></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"77 2","pages":"Pages 59-62"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143373823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A cross-sectional study on the incidence of prosthetic valve thrombosis and its outcome treated with fibrinolysis in a tertiary care hospital","authors":"Dhiviya Murugesan,&nbsp;Balasubramanian Sundaram,&nbsp;Nagasundar Gurusamy,&nbsp;Hemanath Ramamurthy,&nbsp;Nisamudeen Kaja Mohideen","doi":"10.1016/j.ihj.2025.02.003","DOIUrl":"10.1016/j.ihj.2025.02.003","url":null,"abstract":"<div><h3>Aims</h3><div>To find the incidence, risk factors of Prosthetic Valve Thrombosis (PVT)To study the efficacy, outcome and complications of fibrinolysis in PVT.</div></div><div><h3>Methods</h3><div>Data from 44 consecutive patients admitted with PVT treated with fibrinolytics were assessed, outcomes recorded. Only medically managed PVT were included in this study and Surgical management were not included due to inadequate resources.</div></div><div><h3>Results</h3><div>Out of 44 patients, 28 were female and 16 were male with mean age of 36.5 41 had underwent MVR, 3 had underwent DVR. 42 (92.4 %) had thrombus at mitral valve 2 (4.5 %) were at aortic valve. Visible clot was present in 7 (15.9 %) and absent in 37 (84 %) patients. 7 (15.9 %) had recurrent episode of PVT. At the time of thrombolysis, no patient had major bleeding manifestation. During follow up after thrombolysis, 37 (84 %) were alive and 7 (16 %) expired. The incidence of primary end point i.e successful thrombolysis (as defined as complete response without complications) was seen in 61.3 % patients. The secondary end point i.e. Therapeutic failure/death is recorded in 15.9 % study subjects. Among the vulnerable population, therapeutic Failure/death is seen with 57.1 % sub-therapeutic anticoagulant consumers and 42.8 % patients with poor drug compliance.</div></div><div><h3>Conclusion</h3><div>In conclusion this study sheds light on the complexities and challenges associated with prosthetic valve thrombosis in pregnant patients, patients with sub therapeutic anticoagulation or poor drug consumers. This study underscores the importance of close monitoring, optimal anticoagulation, patient education. This study highlights that fibrinolysis unless contraindicated can be considered as effective especially in developing countries or in centres with limited resources, where multiple factors such as surgical availability, financial cost, high operative mortality are to be weighed before treatment.</div></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"77 2","pages":"Pages 63-66"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of hybrid coronary revascularization versus conventional Coronary Artery Bypass surgery in patients with multi-vessel coronary artery disease in a real-world setting: In-hospital outcomes and medium-term follow-up: COHOS study","authors":"Dhamodaran Kaliyamoorthy ,&nbsp;Meeranghani Mohamed Yusuf ,&nbsp;Vadivelu Ramalingam ,&nbsp;Abhishek Kasha ,&nbsp;Manickam Kathiresan ,&nbsp;Rizwan Suliankatchi Abdulkader ,&nbsp;Jeyashree Kathiresan ,&nbsp;Aishwarya Mahesh Kumar ,&nbsp;Elsa Grace ,&nbsp;Anirban Choudhury","doi":"10.1016/j.ihj.2025.03.002","DOIUrl":"10.1016/j.ihj.2025.03.002","url":null,"abstract":"<div><h3>Objectives</h3><div>The aim of this observational study was to evaluate the in-hospital and medium-term outcomes of hybrid coronary revascularization (HCR) in the real-world setting compared to conventional coronary artery bypass grafting (CABG).</div></div><div><h3>Methods</h3><div>All patients with multi-vessel coronary artery disease (MV-CAD) who underwent conventional CABG and HCR in our institution between January 2018 to January 2021 were evaluated in terms of length of intensive care unit (ICU), in-hospital stay, repeat revascularization rates, bleeding, stroke, and in-hospital mortality. Clinical outcomes (mortality and major adverse cardiac and cerebrovascular events [MACCE]) were assessed at average follow up of 3.6 years.</div></div><div><h3>Results</h3><div>Pre-procedural characteristics were balanced between the groups after propensity score matching. There was no significant difference in MACCE [Odds ratio: 0.57; 95 % CI: 0.05 to 1.52; p = 0.66], in-hospital mortality [n = 2 (1.9 %) vs n = 0; p = 0.80], post procedure stroke [n = 2 (1.9 %) vs n = 2 (3.7 %); p = 0.86], post-procedural myocardial infarction requiring repeat revascularization [n = 2 (1.9 %) versus n = 1 (1.9 %); p = 1] during the in-hospital stay of the patients <strong>in the CABG vs HCR groups respectively</strong>. HCR was associated with significantly lower requirement for blood transfusions, bleeding risk, in-hospital stay, and intensive care unit stay. Analysis of the outcomes after 3.6 years revealed no significant difference in MACCE [Odds ratio: 1.40; 95 % CI: 0.46 to 4.30; p = 0.55], and post discharge mortality [n = 0 vs n = 0; p = 1]. Both groups had similar rates of post-procedural myocardial infarction requiring repeat revascularization [n = 0 vs n = 4 (7.4 %); p = 0.278], and rate of re-intervention [n = 0 vs n = 3 (5.6 %); p = 0.41].</div></div><div><h3>Conclusion</h3><div>HCR may be considered as a safe and feasible alternative to conventional CABG in selected individuals with MV-CAD.</div></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"77 2","pages":"Pages 98-104"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}